Ion channel modulating compounds and uses thereof
Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.
1. A method of treating postoperative arrhythmia in a warm-blooded animal in need thereof, comprising administering to said animal a therapeutically effective amount of a composition comprising a compound having the following structure:
as an isolated enantiomeric or diastereomeric isomer or as a mixture thereof, or as a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, excipient or diluent.
2. The method of claim 1 wherein administration is by a route selected from the group consisting of oral, topical, parenteral, sublingual, rectal, vaginal, and intranasal.
3. The method of claim 2 wherein the parenteral administration is selected from the group consisting of subcutaneous injection, intravenous injection, intramuscular injection, epidural injection, intrasternal injection, and infusion.
4. The method of claim 2 wherein the oral administration comprises administering an oral dosage form selected from the group consisting of a powder, a granule, a compressed tablet, a pill, a capsule, a cachet, a chewing gum, a wafer, and a lozenge.
5. The method of claim 1 wherein the arrhythmia is selected from atrial arrhythmia and ventricular arrhythmia.
6. The method of claim 5 wherein the atrial arrhythmia is atrial fibrillation.
7. The method of claim 5 wherein the ventricular arrhythmia is ventricular fibrillation.
8. The method of claim 1 wherein the postoperative arrhythmia occurs following cardiac surgery.
9. The method of claim 8 wherein the cardiac surgery is coronary artery bypass surgery.
10. The method of claim 1 wherein the compound is a mixture of enantiomeric or diastereomeric isomers.
11. The method of claim 10 wherein the compound has the following structure:
or pharmaceutically acceptable salt thereof.
12. The method of claim 10 wherein the compound has the following structure:
or pharmaceutically acceptable salt thereof.
13. The method of claim 1 wherein the compound is an isolated enantiomeric or diastereomeric isomer.
14. The method of claim 13 wherein the compound has the following structure:
or pharmaceutically acceptable salt thereof.
15. The method of claim 13 wherein the compound has the following structure:
or pharmaceutically acceptable salt thereof.
16. The method of claim 13 wherein the compound has the following structure:
or pharmaceutically acceptable salt thereof.
17. The method of claim 13 wherein the compound has the following structure:
or pharmaceutically acceptable salt thereof.
18. The method of claim 15 wherein the pharmaceutically acceptable salt is a monohydrochloride salt.